2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
- PMID: 32860058
- DOI: 10.1093/eurheartj/ehaa575
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Erratum in
-
Corrigendum to: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.Eur Heart J. 2021 May 14;42(19):1908. doi: 10.1093/eurheartj/ehaa895. Eur Heart J. 2021. PMID: 33197246 No abstract available.
-
Corrigendum to: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.Eur Heart J. 2021 May 14;42(19):1925. doi: 10.1093/eurheartj/ehab088. Eur Heart J. 2021. PMID: 33599727 No abstract available.
-
Corrigendum to: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).Eur Heart J. 2021 Jun 14;42(23):2298. doi: 10.1093/eurheartj/ehab285. Eur Heart J. 2021. PMID: 33983428 No abstract available.
-
Correction to: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).Eur Heart J. 2024 Feb 1;45(5):404-405. doi: 10.1093/eurheartj/ehad879. Eur Heart J. 2024. PMID: 38169432 No abstract available.
Keywords: European Society of Cardiology; Guidelines; acute cardiac care; acute coronary syndrome; angioplasty; anticoagulation; antiplatelet; apixaban; aspirin; atherothrombosis; betablockers; bivalirudin; bleedings; bypass surgery; cangrelor; chest pain unit; clopidogrel; dabigatran; diabetes; dual antithrombotic therapy; early invasive strategy; edoxaban; enoxaparin; fondaparinux; glycoprotein IIb/IIIa inhibitors; heparin; high-sensitivity troponin; minoca; myocardial infarction; myocardial ischaemia; nitrates; non-ST-elevation myocardial infarction; platelet inhibition; prasugrel; recommendations; revascularization; rhythm monitoring; rivaroxaban; stent; ticagrelor; triple therapy; unstable angina.
Comment in
-
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation.Eur Heart J. 2021 May 21;42(20):2019. doi: 10.1093/eurheartj/ehaa906. Eur Heart J. 2021. PMID: 33167025 No abstract available.
-
Because of its association with major bleeding the ADP-binding enzyme creatine kinase should be estimated in studies of patients treated for non-ST-segment elevation acute coronary syndromes (NSTE-ACS).Eur Heart J. 2021 Jun 14;42(23):2311-2312. doi: 10.1093/eurheartj/ehaa905. Eur Heart J. 2021. PMID: 33186454 Free PMC article. No abstract available.
-
Major bleeding and the ADP-binding enzyme creatine kinase in non-ST-segment elevation acute coronary syndromes.Eur Heart J. 2021 Jun 14;42(23):2313-2314. doi: 10.1093/eurheartj/ehaa908. Eur Heart J. 2021. PMID: 33186455 No abstract available.
-
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation - Dual versus triple antithrombotic therapy.Eur Heart J. 2021 May 21;42(20):2020-2021. doi: 10.1093/eurheartj/ehaa909. Eur Heart J. 2021. PMID: 33186459 No abstract available.
-
High-risk NSTE-ACS: high time for robust data.Eur Heart J. 2021 Jan 21;42(4):352. doi: 10.1093/eurheartj/ehaa927. Eur Heart J. 2021. PMID: 33188591 Free PMC article. No abstract available.
-
Optimal timing of invasive angiography in non-ST-segment elevation acute coronary syndromes-do we need more data?Eur Heart J. 2021 Jan 21;42(4):353-354. doi: 10.1093/eurheartj/ehaa930. Eur Heart J. 2021. PMID: 33188593 No abstract available.
-
Prasugrel over ticagrelor in non-ST-elevation acute coronary syndromes: is it justified?Eur Heart J. 2021 Jul 8;42(26):2609-2610. doi: 10.1093/eurheartj/ehaa880. Eur Heart J. 2021. PMID: 33205147 No abstract available.
-
Lesson learnt from the new 2020 ESC guidelines on NSTE-ACS: when clinical judgement precedes and overpasses weak recommendations.Eur Heart J. 2021 Jul 8;42(26):2605-2606. doi: 10.1093/eurheartj/ehaa858. Eur Heart J. 2021. PMID: 33205151 No abstract available.
-
Prasugrel over ticagrelor in non-ST-elevation acute coronary syndromes: is it justified?Eur Heart J. 2021 Jul 8;42(26):2611-2612. doi: 10.1093/eurheartj/ehaa883. Eur Heart J. 2021. PMID: 33205156 No abstract available.
-
Lesson learnt from the new 2020 ESC guidelines on non-ST-segment elevation acute coronary syndrome: when clinical judgement precedes and overpasses weak recommendations. 2020 non-ST-segment elevation acute coronary syndrome guidelines on pre-treatment: primum non nocere!Eur Heart J. 2021 Jul 8;42(26):2607-2608. doi: 10.1093/eurheartj/ehaa861. Eur Heart J. 2021. PMID: 33205199 No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical